<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281292</url>
  </required_header>
  <id_info>
    <org_study_id>LKA651X-2101</org_study_id>
    <nct_id>NCT02281292</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema</brief_title>
  <official_title>A Randomized, Sham Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Institutes for BioMedical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the initial safety of intravitreal (IVT) LKA651 and&#xD;
      potential for use alone or in combination with Ranibizumab ophthalmic solution (Lucentis®)&#xD;
      for the treatment of Diabetic Macular Edema (DME) in patients with symptomatic disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first-in-human study will be conducted in 2 parts. Part 1 is an ascending dose design to&#xD;
      assess the safety, tolerability, pharmacodynamics and pharmacokinetics of various single IVT&#xD;
      doses of LKA651 in up to 48 subjects with diabetic macular edema. Subjects will be randomized&#xD;
      to receive active or sham injections in a 3:1 ratio. A total of 6 cohorts (8 subjects per&#xD;
      cohort) may be enrolled in Part 1. Each subject will participate in a screening/eligibility&#xD;
      period (up to 60 days), a treatment period (single day), and an 84 day follow up period. A&#xD;
      total of up to 11 visits will take place, all on an out-patient basis. An independent data&#xD;
      monitoring committee (DMC) will be chartered to review cumulative safety data and approve&#xD;
      each dose escalation and cohort progression in this first-in-human trial.&#xD;
&#xD;
      Part 2 is a double-masked design to assess the safety/tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of a single IVT dose of LKA651 when co-administered with Lucentis®. A total&#xD;
      of up to 3 cohorts (8 subjects per cohort) may be enrolled in Part 2. Each subject will&#xD;
      participate in a screening/eligibility period (up to 60 days), a treatment period&#xD;
      (combination therapy, single day), and an 84 day follow up period. A total of up to 11 visits&#xD;
      will take place, all on an out-patient basis. For the LKA651 vs sham injections, the unmasked&#xD;
      ophthalmologist is not permitted to do any of the assessments except for the injection (and&#xD;
      an inspection of the injection site immediately following). All other ocular assessments&#xD;
      after randomization will be conducted by a second ophthalmologist masked to the type of&#xD;
      injection (active or sham). The Lucentis injection (Part 2) is given open label to all&#xD;
      patients following either the LKA651 or sham injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Management Decision&#xD;
  </why_stopped>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with a serious adverse event (SAE) that, in the opinion of the investigator, is related to the study drug</measure>
    <time_frame>Up to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects experiencing a non-serious adverse event</measure>
    <time_frame>Up to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [mass x time / volume] (AUC(0-tlast))</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Contingent upon observed serum concentration levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the serum concentration-time curve from time zero to time 't' where t is a defined time point after administration [mass x time / volume] (AUC (0-t))</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Contingent upon observed serum concentration levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The observed maximum serum concentration following drug administration [mass / volume] (Cmax)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Contingent upon observed serum concentration levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to reach the maximum serum concentration after drug administration [time] (Tmax)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Contingent upon observed serum concentration levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dose normalized observed maximum serum concentration following drug administration [mass*dose / volume] (Cmax/D)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Contingent upon observed serum concentration levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dose-normalized area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [mass*dose x time / volume] (AUC/D)</measure>
    <time_frame>Up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central subfield thickness</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Contingent upon observed serum concentration levels</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>LKA651 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LKA651 ophthalmic solution in 1 of 5 concentrations, administered as a single IVT injection in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham injection (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham injection in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LKA651 and Lucentis (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LKA651 ophthalmic solution in 1 of 3 concentrations, administered as a single IVT injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham injection and Lucentis (Part 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LKA651 ophthalmic solution</intervention_name>
    <arm_group_label>LKA651 (Part 1)</arm_group_label>
    <arm_group_label>LKA651 and Lucentis (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ranibizumab ophthalmic solution</intervention_name>
    <arm_group_label>LKA651 and Lucentis (Part 2)</arm_group_label>
    <arm_group_label>Sham injection and Lucentis (Part 2)</arm_group_label>
    <other_name>Lucentis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>Mock injection administered as an empty hub without needle</description>
    <arm_group_label>Sham injection (Part 1)</arm_group_label>
    <arm_group_label>Sham injection and Lucentis (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained.&#xD;
&#xD;
          -  Type 1 or type 2 diabetes that is actively managed by a physician and hemoglobin A1C ≤&#xD;
             12% at screening/eligibility.&#xD;
&#xD;
          -  Negative pregnancy test results at screening/eligibility and pre-injection on&#xD;
             treatment day.&#xD;
&#xD;
          -  Diabetic macular edema (DME) with center involvement in at least one eye, including&#xD;
             those with focal or diffuse DME.&#xD;
&#xD;
          -  ETDRS letter score in the study eye of 55 letters or worse (approximate Snellen&#xD;
             equivalent of 20/80). The non-study eye (fellow eye) should be ≥ 60 letters or better&#xD;
             (approximate Snellen equivalent of 20/63) at Day 1 pre-dose.&#xD;
&#xD;
          -  Safe to withhold treatment of the study eye with laser photocoagulation, intravitreal&#xD;
             steroid injection, or intravitreal vascular endothelial growth factor (VEGF) inhibitor&#xD;
             (Part 1) for the duration of the study.&#xD;
&#xD;
          -  Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Proliferative diabetic retinopathy in the study eye, with the exception of tufts of&#xD;
             neovascularization less than 1 disc area with no vitreous hemorrhage.&#xD;
&#xD;
          -  Any progressive disease of the retina (e.g. uveitis, rod-cone dystrophy) or optic&#xD;
             nerve (e.g. glaucoma) other than diabetic retinopathy.&#xD;
&#xD;
          -  Any active infection involving ocular adnexa including infectious conjunctivitis,&#xD;
             keratitis, scleritis, endophthalmitis, as well as idiopathic or autoimmune-associated&#xD;
             uveitis in either eye.&#xD;
&#xD;
          -  Ocular disorders in the study eye that may confound interpretation of study results,&#xD;
             including retinal vascular occlusion, retinal detachment, macular hole, or choroidal&#xD;
             neovascularization of any cause (e.g., AMD, ocular histoplasmosis, or pathologic&#xD;
             myopia).&#xD;
&#xD;
          -  Cataract surgery in the study eye, Yttrium-Aluminum-Garnet (YAG) laser capsulotomy or&#xD;
             any intraocular surgery within the past 6 months preceding Day 1.&#xD;
&#xD;
          -  Use of systemic anticoagulant therapy during the study, e.g., warfarin, heparin, etc.&#xD;
             The use of aspirin is not an exclusion.&#xD;
&#xD;
          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives&#xD;
             of enrollment, whichever is longer; or longer if required by local regulations.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women.&#xD;
&#xD;
          -  Women of child-bearing potential, unless using highly effective methods of&#xD;
             contraception during dosing of study treatment.&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Clinical Scientist, CSI, ID/Ophtha</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2014</study_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>Intravitreal</keyword>
  <keyword>Retina</keyword>
  <keyword>Ophthalmology</keyword>
  <keyword>Lucentis</keyword>
  <keyword>OCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

